iRadimed (NASDAQ:IRMD) Stock Passes Above Fifty Day Moving Average – Here’s What Happened

iRadimed Corporation (NASDAQ:IRMD)’s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $90.92 and traded as high as $96.74. iRadimed shares last traded at $96.42, with a volume of 154,713 shares trading hands.

Analyst Ratings Changes

Several research analysts have commented on the company. Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Roth Mkm restated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. Weiss Ratings lowered shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. Finally, Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $120.00.

iRadimed Trading Up 2.2%

The business has a 50-day moving average of $90.92 and a two-hundred day moving average of $95.78. The firm has a market cap of $1.23 billion, a P/E ratio of 52.69 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.8%. iRadimed’s payout ratio is presently 43.72%.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $100.38, for a total value of $501,900.00. Following the transaction, the chief executive officer owned 2,235,000 shares in the company, valued at approximately $224,349,300. The trade was a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 62,500 shares of company stock valued at $5,794,878 over the last quarter. 36.80% of the stock is owned by insiders.

Institutional Trading of iRadimed

A number of large investors have recently bought and sold shares of IRMD. Vanguard Group Inc. raised its position in shares of iRadimed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after acquiring an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of iRadimed by 4.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock valued at $21,768,000 after purchasing an additional 9,017 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after purchasing an additional 55,426 shares during the period. Finally, State Street Corp grew its stake in iRadimed by 3.1% during the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock worth $18,770,000 after purchasing an additional 5,713 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.